pf02413873
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2008 (NCT00800618)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Progesterone receptorANTAGONIST
PGR antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 4-(3-cyclopropyl-1-(methylsulfonylmethyl)-5-methyl-1h-pyrazol-4-yl)oxy-2,6-dimethylbenzonitrile
- pf02413873
- pf 02413873
- pf-02413873
- pf-02413873
- pf-02413873
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00857571 | Phase 1 | Apr 1, 2009 | Pfizer |
| NCT00828867 | Phase 1 | Nov 14, 2008 | GlaxoSmithKline |
| NCT00800618 | Phase 1 | Nov 1, 2008 | Pfizer |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 2 | 2 | 1 | 2008 |
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2008 |
2 organizations
Page 1 / 1